TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8369579
Drug: Cyclosporin maintenance
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin maintenance therapy 2.5‐5 mg/kg/day
Study: 29482397
Drug: Dual-pulsed 532-nm/1064-nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-pulsed 532-nm/1064-nm QS laser treatment
Study: 29482397
Drug: Single-pulsed 1064-nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-pulsed 1064-nm Nd:YAG laser treatment
Study: 24304551
Drug: rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (20 mg 12 hours before coronary angiography + 20 mg immediately before PCI)
Study: 24304551
Drug: PCI without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCI without statin therapy (control group)
Study: 22394023
Drug: Dowels stored
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dowels stored for 30 days in aqueous solution at 37°C
Study: 19706212
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid supplements (IFA; 60 mg Fe, 500 microg folic acid)
Study: 19706212
Drug: Leaf concentrate
Normalized name: Belladonna Leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaf concentrate (LC; 5 mg Fe, 13 microg folic acid)
Study: 23724913
Drug: Crizotinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (250 mg orally twice daily)
Study: 26483333
Drug: Chemotherapy (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (docetaxel 75 mg/m2 every three weeks)
Study: 23672993
Drug: AHR-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHR-guided treatment strategy
Study: 21719901
Drug: CHO solution
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO solution (1.2 g CHO/kg body mass)
Study: 7490363
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of UVA/UVB sunscreen for 24 months
Study: 9684126
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg once daily)
Study: 11802750
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg once daily)
Study: 3126527
Drug: R 58
Normalized name: dextromethorphan HBr 58 MG / guaifenesin 1000 MG 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 58 735 (5 mg b.i.d. for 2 days followed by 10 mg b.i.d. for 5 days)
Study: 25555191
Drug: 50% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% dose of verteporfin (PDT)
Study: 25555191
Drug: 30% dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% dose of verteporfin (PDT)
Study: 24004887
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1500 mg Ca/d)
Study: 7180065
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (1.5 g)
Study: 9039270
Drug: SP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP plus daily iron (SPD)
Study: 8115073
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron therapy
Study: 7657848
Drug: Isradipine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (1.25 mg twice daily)
Study: 8466728
Drug: Methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (250 mg twice daily)
Study: 8466728
Drug: Isradipine +
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine + Captopril (25 mg or 50 mg once daily for non-responders)
Study: 8466728
Drug: Methyldopa +
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa + Captopril (25 mg or 50 mg once daily for non-responders)
Study: 8466728
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Captopril (25 mg or 50 mg once daily for non-responders)
Study: 26859648
Drug: Phytic combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytic combination peels
Study: 20731529
Drug: ATOR 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATOR 20 mg up-titrated to 80 mg
Study: 20731529
Drug: ROSU 10
Normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ROSU 10 mg up-titrated to 40 mg
Study: 8206564
Drug: Hydrochlorothiazide with
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide with oral potassium
Study: 8206564
Drug: Hydrochlorothiazide with
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide with oral potassium and magnesium
Study: 24727483
Drug: Extended, nontailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended, nontailored treatments (12 weeks of counseling, nicotine replacement, and bupropion)
Study: 15998356
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 3 months
Study: 1823041
Drug: Nd-YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd-YAG laser treatment
Study: 2844549
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg b.i.d. for one month
Study: 11420579
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) plus standard medical therapy for CHF
Study: 11420579
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy for CHF
Study: 15248223
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg, twice weekly, subcutaneous injection)
Study: 9638413
Drug: Multimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality therapy combining pancreatic resection with neo‐ and adjuvant locoregional targeting immunochemotherapy (Group A)
Study: 2492234
Drug: Leuprolide, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide, 1 mg subcutaneously per day, administered from the midluteal phase before IVF treatment
Study: 4855496
Drug: Orotic acid
Normalized name: Orotic acid
DrugBank: Orotic acid (DB02262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orotic acid (100 mg/kg/day) orally in 2 daily doses from 1st to 5th day of life
Study: 27943522
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 40 ml of 0.25% bupivacaine
Study: 27943522
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 40 ml of 0.25% bupivacaine
Study: 25378135
Drug: Intravenous firocoxib
Normalized name: Firocoxib
DrugBank: Firocoxib (DB09217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous firocoxib (57 mg)
Study: 25378135
Drug: Oral paste
Normalized name: Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paste firocoxib (57 mg)
Study: 3519879
Drug: no therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: no therapy until relapse, then treatment with BCP
Study: 30099128
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment response for NE
Study: 30099128
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to LUTS treatment
Study: 22758791
Drug: Protamine zinc
Normalized name: Protamine zinc insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine zinc recombinant human insulin (PZIR) at 0.3 U/kg
Study: 22758791
Drug: Protamine zinc
Normalized name: Protamine zinc insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine zinc recombinant human insulin (PZIR) at 0.8 U/kg at three separate sites
Study: 19074911
Drug: Abatacept (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (approximately 10 mg/kg)
Study: 9888410
Drug: OTZ (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTZ (70 mg/kg IV every 8 hours for 9 days)
Study: 1981319
Drug: Prazosin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.25 mg i.v.)
Study: 19464535
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) vaccination with 3.0 microg HA
Study: 19464535
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) vaccination with 6.0 microg HA
Study: 19464535
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) vaccination with 15.0 microg HA
Study: 19464535
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) vaccination
Study: 19464535
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) vaccination
Study: 7957006
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil plus psyllium fibre (20 g/day)
Study: 7957006
Drug: Coconut oil
Normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut oil plus psyllium fibre (20 g/day)
Study: 1728438
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg p.o.)
Study: 2122618
Drug: Chemoembolization (CHE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoembolization (CHE) as initial therapy
Study: 2122618
Drug: Chemoembolization (CHE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoembolization (CHE) with additional portal vein chemotherapy
Study: 49561
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose plus electrolytes as a maintenance solution
Study: 49561
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose plus electrolytes
Study: 49561
Drug: Oral glucose‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose‐electrolyte solutions
Study: 19851433
Drug: Dextrose tablet
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose tablet (6 g)
Study: 19851433
Drug: Buccal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal glucose spray (10 doses, 0.84 g of glucose)
Study: 16830288
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 2x400 mg, metronidazole 3x500 mg, and tetracycline 2x1000 mg for 14 days (RMT group)
Study: 16830288
Drug: Pantoprazole 2x40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 2x40 mg, bismuth subcitrate 4x300 mg, amoxicillin 2x1000 mg, and clarithromycin 2x500 mg for 14 days (PBAC group)
Study: 11378663
Drug: OMC (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC (40 mg omeprazole once a day, 500 mg metronidazole and 250 mg clarithromycin twice daily for 7 days)
Study: 11378663
Drug: NA (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA (300 mg nizatidine once a day and 1000 mg amoxicillin twice daily for 14 days)
Study: 2887885
Drug: Atenolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (10 mg IV every 6 h for 3 days, then 100 mg orally daily for 4 days)
Study: 30841030
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg/kg over 3 min
Study: 25660046
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (saline)
Study: 23238118
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation program (twice‐weekly training for 12 weeks starting 1 month after hospital discharge)
Study: 10473925
Drug: Cefepime (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2.0 g q. 8 h)
Study: 8935482
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan 100 mg (first dose)
Study: 8935482
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan 100 mg (second dose)
Study: 23238499
Drug: inactive nasal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive nasal spray + calcium 500 mg
Study: 20404307
Drug: Canakinumab (anti-interleukin-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (anti-interleukin-1 therapy)
Study: 4902494
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution
Study: 111945
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of glucose
Study: 365312
Drug: Oral 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-fluorouracil (5-FU)
Study: 365312
Drug: Oral Methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Methyl CCNU
Study: 31566030
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily for 5 days
Study: 12607793
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg once daily for 5 days
Study: 31566030
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 5 days
Study: 30879775
Drug: Cavit G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavit G (3M ESPE)
Study: 28244907
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (1 g bolus)
Study: 28244907
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (1.95 g orally 2 hours preoperatively)
Study: 25823907
Drug: 2-week buprenorphine
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week buprenorphine taper
Study: 21323599
Drug: High-normal target
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-normal target TSH (2.0-4.0 mIU/L)
Study: 17934662
Drug: Glimepiride 4
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 4 mg (Amaryl)
Study: 15525713
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of trivalent inactivated influenza vaccine (6 mug of hemagglutinin per antigen)
Study: 15525713
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of standard dose of trivalent inactivated influenza vaccine (15 mug of hemagglutinin per antigen)
Study: 7574735
Drug: Plachitin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plachitin (300 mg, 100 mg as CDDP) - Group A
Study: 7574735
Drug: Plachitin particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plachitin particles (300 mg) - Group B
Study: 7574735
Drug: CDDP (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP (100 mg) - Group C
Study: 2114208
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied cromolyn solution
Study: 31602695
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus capsules (30 mg daily, 15 mg twice/day)
Study: 31602695
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (twice/day)
Study: 31602695
Drug: Crocus sativus
Normalized name: CROCUS SATIVUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocus sativus capsules
Study: 28156154
Drug: Insulin timing
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin timing intervention (injected or infused 30 minutes before the meal to 15 minutes after the meal)
Study: 28156154
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard insulin timing)
Study: 28156154
Drug: Insulin timing
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin timing intervention (for volunteers with baseline A1C in the upper half)
Study: 12939313
Drug: Adrenomedullin co-infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenomedullin co-infused with N(G)‐monomethyl‐L‐arginine (3 mg/kg bolus and 30 micro g/(kg. min) continuous intravenous infusion)
Study: 6997374
Drug: Revaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccination with ACI vaccine
Study: 6997374
Drug: ACI vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACI vaccine, 'Vaxgrip', and 'Mutagripe'
Study: 30037208
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g IV before induction, followed by 1 g IV infusion at 8-hour intervals for 48 hours)
Study: 17372174
Drug: Oral deferiprone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral deferiprone 75 mg/kg per day (combined group)
Study: 9709942
Drug: 16 mg/day
Normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/day DHT gel
Study: 9709942
Drug: 32 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg/day DHT gel
Study: 7930274
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose subcutaneous heparin (12,500 U every 12 h delayed until 4 h after the end of streptokinase therapy)
Study: 3259071
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments
Study: 29243341
Drug: 2% carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% carteolol hydrochloride drops administered to the lesion surface twice daily for 6 months
Study: 27306192
Drug: Ziprasidone augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone augmentation
Study: 20923712
Drug: Cerebrolysin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (30 mL)
Study: 17953718
Drug: Febuxostat 120
Normalized name: Febuxostat 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 120 mg (single dosing)
Study: 16586149
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (0.35 mg hydroxytyrosol)
Study: 16586149
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (1.7 mg hydroxytyrosol)
Study: 17258718
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg/day
Study: 3906673
Drug: Baclofen (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (25 to 60 mg per day)
Study: 3906673
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 to 40 mg per day)
Study: 27442674
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg loading before anesthesia induction and 0.3 μg/kg/h infusion during surgery)
Study: 21069596
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MT) treatment with three cycles of 12 active sessions each, three times a week for one month, followed by one month of no treatment
Study: 17706003
Drug: Aripiprazole (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (starting dose 15 mg/day, adjusted 10-30 mg/day)
Study: 9563219
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 mg twice daily for seven days)
Study: 8129128
Drug: Alfentanil 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 0.2 mg
Study: 12930014
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide vaginal douching (20 ml of 3% hydrogen peroxide)
Study: 8846276
Drug: 25 G
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 G Quincke needle
Study: 8846276
Drug: 29 G
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29 G Quincke needle
Study: 16650261
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide (50% N2O/50% O2)
Study: 8828672
Drug: Autologous erythrocyte
Normalized name: erythrocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous erythrocyte infusion (700-ml infusion, 42% hematocrit)
Study: 1385599
Drug: New combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: New combination and selection of items reflecting different facets of depression
Study: 31074816
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 intake ≥35 mg/d
Study: 31074816
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 intake ≥30 μg/d
Study: 7489435
Drug: Ketorolac 0.5
Normalized name: KETOROLAC 0.5/PHENYLEPHRINE2.5/PROPARACAINE0.5/TROPICAMIDE 1%OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.5 mg/kg
Study: 8193492
Drug: Pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 1 mg/kg
Study: 24350872
Drug: Intensive anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive anti-hypertensive therapy with a systolic target of <140 mmHg within one hour
Study: 24350872
Drug: Standard guideline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard guideline recommended treatment of <180 mmHg
Study: 24350872
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Intensive and Standard treatment)
Study: 15927285
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration (27 patients)